Abstract
Vero cells can be used as host for the production of many different types of viruses. The standard Vero culturing process consists of growing Vero cells adherent to microcarriers. Due to surface limitation the cells will have to be transferred to new microcarriers regularly. This subculturing of the cells, especially at large scale, is a complicated technique. This drawback can be overcome by using single cell suspension cultures. Vero cells growing in single cell suspension (sVero) were compared to adherent growing Vero cells (aVero) for their capability of producing polio virus. Using flow cytometry it was determined that sVero cells contained the polio virus receptor and were able to produce polio virus. These results indicate that sVero cells may be an ideal candidate for a platform based viral vaccine production approach. The combination of sVero cells with the flexibility of disposable bioreactors completes their suitability for these purposes.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Barrett PN, Mundt W, Kistner O, Howard MK. 2009. Vero cell platform in vaccine production: moving towards cell culture-based viral vaccines. Expert Rev Vaccines 8:607–618.
Kersten G, Hazendonk T, Beuvery C. 1999. Antigenic and immunogenic properties of inactivated polio vaccine made from Sabin strains. Vaccine 17:2059–2066.
Kistner O, Howard MK, Spruth M, Wodal W, Bruhl P, Gerencer M, Crowe BA, Savidis-Dacho H, Livey I, Reiter M, Mayerhofer I, Tauer C, Grillberger L, Mundt W, Falkner FG, Barrett PN. 2007. Cell culture (Vero) derived whole virus (H5N1) vaccine based on wild-type virus strain induces cross-protective immune responses. Vaccine 25:6028–6036.
Mendelsohn CL, Wimmer E, Racaniello VR. 1989. Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56:855–865.
Montagnon BJ, Fanget B, Nicolas AJ. 1981. The large-scale cultivation of VERO cells in micro-carrier culture for virus vaccine production. Preliminary results for killed poliovirus vaccine. Dev Biol Stand 47:55–64.
Oda T, Ohka S, Nomoto A. 2004. Ligand stimulation of CD155alpha inhibits cell adhesion and enhances cell migration in fibroblasts. Biochem Biophys Res Commun 319:1253–1264.
Paillet C, Forno G, Kratje R, Etcheverrigaray M. 2009. Suspension-Vero cell cultures as a platform for viral vaccine production. Vaccine 27:6464–6467.
van Wezel AL. 1967. Growth of cell-strains and primary cells on micro-carriers in homogeneous culture. Nature 216:64–65.
van Wezel AL, van Herwaarden JA, van de Heuvel-de Rijk EW. 1979. Large-scale concentration and purification of virus suspension from microcarrier culture for the preparation of inactivated virus vaccines. Dev Biol Stand 42:65–69.
World Health Organization. 1998. Requirements for the use of animal cells as in vitro substrates for the production of biologicals.WHO Technical Report Series. pp 20–53.
Zhang P, Mueller S, Morais MC, Bator CM, Bowman VD, Hafenstein S, Wimmer E, Rossmann MG. 2008. Crystal structure of CD155 and electron microscopic studies of its complexes with polioviruses. Proc Natl Acad Sci 105:18284–18289.
Acknowledgements
We thank Guillermina Forno from Zelltek S.A. and Marina Etcheverrigaray from the Universidad Nacional del Litoral, Argentina for providing the sVero cells.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2012 Springer Science+Business Media B.V.
About this paper
Cite this paper
Thomassen, Y.E., van Eikenhorst, G., van der Pol, L.A., Bakker, W.A. (2012). Platform Technology for Viral Vaccine Production: Comparison Between Attached and Suspension Vero Cells. In: Jenkins, N., Barron, N., Alves, P. (eds) Proceedings of the 21st Annual Meeting of the European Society for Animal Cell Technology (ESACT), Dublin, Ireland, June 7-10, 2009. ESACT Proceedings, vol 5. Springer, Dordrecht. https://doi.org/10.1007/978-94-007-0884-6_115
Download citation
DOI: https://doi.org/10.1007/978-94-007-0884-6_115
Published:
Publisher Name: Springer, Dordrecht
Print ISBN: 978-94-007-0883-9
Online ISBN: 978-94-007-0884-6
eBook Packages: Biomedical and Life SciencesBiomedical and Life Sciences (R0)